567 related articles for article (PubMed ID: 32305131)
1. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
Song Y; Liu Q; Zuo T; Wei G; Jiao S
Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
[TBL] [Abstract][Full Text] [Related]
2. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
5. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
Zhu H; You Y; Shen Z; Shi L
Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
[TBL] [Abstract][Full Text] [Related]
6. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
7. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.
Choi BD; Yu X; Castano AP; Darr H; Henderson DB; Bouffard AA; Larson RC; Scarfò I; Bailey SR; Gerhard GM; Frigault MJ; Leick MB; Schmidts A; Sagert JG; Curry WT; Carter BS; Maus MV
J Immunother Cancer; 2019 Nov; 7(1):304. PubMed ID: 31727131
[TBL] [Abstract][Full Text] [Related]
9. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.
Cui J; Zhang Q; Song Q; Wang H; Dmitriev P; Sun MY; Cao X; Wang Y; Guo L; Indig IH; Rosenblum JS; Ji C; Cao D; Yang K; Gilbert MR; Yao Y; Zhuang Z
Neuro Oncol; 2019 Nov; 21(11):1436-1446. PubMed ID: 31276594
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma.
Agliardi G; Liuzzi AR; Hotblack A; De Feo D; Núñez N; Stowe CL; Friebel E; Nannini F; Rindlisbacher L; Roberts TA; Ramasawmy R; Williams IP; Siow BM; Lythgoe MF; Kalber TL; Quezada SA; Pule MA; Tugues S; Straathof K; Becher B
Nat Commun; 2021 Jan; 12(1):444. PubMed ID: 33469002
[TBL] [Abstract][Full Text] [Related]
14. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
15. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab.
Kato D; Yaguchi T; Iwata T; Katoh Y; Morii K; Tsubota K; Takise Y; Tamiya M; Kamada H; Akiba H; Tsumoto K; Serada S; Naka T; Nishimura R; Nakagawa T; Kawakami Y
Elife; 2020 Mar; 9():. PubMed ID: 32228854
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
17. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
18. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
19. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
[TBL] [Abstract][Full Text] [Related]
20. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
Andreu-Saumell I; Rodriguez-Garcia A; Mühlgrabner V; Gimenez-Alejandre M; Marzal B; Castellsagué J; Brasó-Maristany F; Calderon H; Angelats L; Colell S; Nuding M; Soria-Castellano M; Barbao P; Prat A; Urbano-Ispizua A; Huppa JB; Guedan S
Nat Commun; 2024 Apr; 15(1):3552. PubMed ID: 38670972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
